GlassScriptPhysician profile
Megan Eileen Laplaca
NPI 1619714474
$2,660.28
in general payments reported to CMS, 2019-2025
33 companies · $2,660 in 2025
The $2,660 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $2,660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,585 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,585.29 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $350.23 | 2025 | Tagrisso, Calquence, Lynparza |
| Eisai INC. | $186.86 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $177.41 | 2025 | Fruzaqla, Iclusig |
| Genzyme Corporation | $144.18 | 2025 | |
| Caris Mpi, INC. | $126.93 | 2025 | Mi Cancer Seek |
| E.R. Squibb & Sons, L.L.C. | $120.65 | 2025 | Opdivo |
| Novartis Pharmaceuticals Corporation | $118.38 | 2025 | |
| Amgen INC. | $117.00 | 2025 | Kyprolis |
| Glaxosmithkline, LLC. | $110.28 | 2025 | Ojjaara, Zejula, Jemperli |
| Ipsen Biopharmaceuticals, INC | $107.75 | 2025 | Onivyde |
| Astellas Pharma US INC | $93.12 | 2025 | Xtandi |
| Jazz Pharmaceuticals INC. | $87.03 | 2025 | |
| Merck Sharp & Dohme LLC | $75.88 | 2025 | Keytruda, Keytruda Qlex, Welireg |
| Beone Medicines USA, INC. | $75.34 | 2025 | Brukinsa, Tevimbra |
| Lilly USA, LLC | $73.76 | 2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $73.50 | 2025 | |
| Incyte Corporation | $70.23 | 2025 | Jakafi, Zynyz, Monjuvi |
| Bayer Healthcare Pharmaceuticals INC. | $69.09 | 2025 | |
| Tersera Therapeutics LLC | $61.64 | 2025 | Xermelo |
| Karyopharm Therapeutics INC. | $56.76 | 2025 | Xpovio |
| Abbvie INC. | $50.33 | 2025 | |
| Servier Pharmaceuticals LLC | $49.20 | 2025 | |
| Progenics Pharmaceuticals, INC. | $38.08 | 2025 | |
| Adc Therapeutics America, INC. | $33.58 | 2025 | |
| Taiho Oncology, INC. | $28.84 | 2025 | |
| Daiichi Sankyo INC. | $27.54 | 2025 | Enhertu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.88 | 2025 | |
| Sobi, INC | $23.58 | 2025 | |
| Genentech USA, INC. | $22.38 | 2025 | Polivy |
| Pharmacosmos Therapeutics INC. | $22.05 | 2025 | Monoferric |
| Legend Biotech USA INC. | $15.74 | 2025 | Carvykti |
| Agios Pharmaceuticals, INC. | $14.08 | 2025 | Pyrukynd |
| Janssen Biotech, INC. | $13.98 | 2025 | Darzalex, Talvey |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Laplaca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.